Biopharmaceutical company Foresee Pharmaceuticals (TPEx:6576) announced on Sunday that it has successfully completed its Phase 1 single and multiple ascending dose clinical study in Australia for linvemastat (FP-020), a selective oral MMP-12 inhibitor.

The trial evaluated safety, tolerability, and pharmacokinetics in healthy subjects, with 40 participants in the single dose phase and 24 in the multiple dose phase.

Linvemastat is designed to treat inflammatory and fibrotic diseases, offering greater potency and selectivity than its predecessor, aderamastat (FP-025). Preclinical studies show favorable efficacy in respiratory and inflammatory bowel diseases. MMP-12, a key immune-fibrotic modulator, is linked to disease severity in asthma and COPD. Foresee plans to advance linvemastat for respiratory and fibrotic conditions.